Patients
allergic reactions
ALLERGIC REACTION
Participants were recruited from the University of Navarra COVID19 Program (Inclusion criteria included to be over 18 years-old and to have a positive SARS-CoV-2 PCR (<27 cycles) in the last 48 hours. Concomitant medications except angiotensin receptor blockers or immunosuppressant agents were allowed. All patients consented to receive either PDT or placebo equivalent. Patients with severe comorbidities or moderate-severe COVID-19 were not included. Individuals who reported inability to tolerate insertion of the light illuminator due to oronasal size, shape, or anatomical variants, those with known allergic reactions to components of the nasal decolonization treatment including methylene blue, and those unable to attend the follow-up appointments were excluded.